LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

NVS

150.9

-0.44%↓

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

NVS

150.9

-0.44%↓

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

NVS

150.9

-0.44%↓

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

NVS

150.9

-0.44%↓

LLY

1,122.06

-0.63%↓

JNJ

235.31

-0.25%↓

ABBV

222.61

+0.73%↑

UNH

408.57

-0.43%↓

NVS

150.9

-0.44%↓

Search

TransMedics Group Inc

Cerrado

SectorSanidad

75.73 0.8

Resumen

Variación precio

24h

Actual

Mínimo

73.75

Máximo

76.68

Métricas clave

By Trading Economics

Ingresos

-98M

7.3M

Ventas

13M

174M

P/B

Media del Sector

17.272

49.712

BPA

0.3

Margen de beneficios

4.206

Empleados

898

EBITDA

-4.9M

28M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+58.49% upside

Dividendos

By Acuity

Próximas Ganancias

29 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-745M

2.6B

Apertura anterior

74.93

Cierre anterior

75.73

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

166 / 342 Clasificación en Healthcare

TransMedics Group Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Acerca de TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat